Abstract:Human alpha‐1‐antitrypsin (A1AT), a native serine‐protease inhibitor that protects tissue damage from excessive protease activities, is used as an augmentation therapy to treat A1AT‐deficienct patients. However, A1AT is sensitive to oxidation‐mediated deactivation and has a short circulating half‐life. Currently, there is no method that can effectively protect therapeutic proteins from oxidative damage in vivo. Here we developed a novel biocompatible selenopolypeptide and site‐specifically conjugated it with A… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.